Elanzanetant is a non-hormonal compound for the treatment of vasomotor symptoms associated with menopause that specifically targets both NK1 and NK –3 receptors.
Elanzanetant is efficacious, well tolerated as a selective neurokin 1,3 receptor antagonist for the treatment of moderate to severe VMS associated with menopause
Elanzanetant also improves sleep, disturbances, and menopause related quality of life.